Genetically modified mesenchymal stem cells: The next generation of stem cell-based therapy for TBI
Date
2020Journal
International Journal of Molecular SciencesPublisher
MDPI AGType
Article
Metadata
Show full item recordAbstract
Mesenchymal stem cells (MSCs) are emerging as an attractive approach for restorative medicine in central nervous system (CNS) diseases and injuries, such as traumatic brain injury (TBI), due to their relatively easy derivation and therapeutic effect following transplantation. However, the long-term survival of the grafted cells and therapeutic efficacy need improvement. Here, we review the recent application of MSCs in TBI treatment in preclinical models. We discuss the genetic modification approaches designed to enhance the therapeutic potency of MSCs for TBI treatment by improving their survival after transplantation, enhancing their homing abilities and overexpressing neuroprotective and neuroregenerative factors. We highlight the latest preclinical studies that have used genetically modified MSCs for TBI treatment. The recent developments in MSCs' biology and potential TBI therapeutic targets may sufficiently improve the genetic modification strategies for MSCs, potentially bringing effective MSC-based therapies for TBI treatment in humans. Copyright 2020 by the authors.Keyword
Cell therapyGene therapy
Genetic modification
Mesenchymal stem cells
Neurogenesis
Traumatic brain injury
Identifier to cite or link to this item
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85086167484&doi=10.3390%2fijms21114051&partnerID=40&md5=df3b63a67dcaaa4321bb0fbf6be95c1e; http://hdl.handle.net/10713/13089ae974a485f413a2113503eed53cd6c53
10.3390/ijms21114051